KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Cash from Discontinued OperationsCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Cash from Operations (2016 - 2025)

Historic Cash from Operations for TherapeuticsMD (TXMD) over the last 16 years, with Q3 2025 value amounting to $999000.0.

  • TherapeuticsMD's Cash from Operations rose 150704.23% to $999000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.1 million, marking a year-over-year increase of 15505.65%. This contributed to the annual value of $1.2 million for FY2024, which is 10506.91% up from last year.
  • Per TherapeuticsMD's latest filing, its Cash from Operations stood at $999000.0 for Q3 2025, which was up 150704.23% from $381000.0 recorded in Q2 2025.
  • Over the past 5 years, TherapeuticsMD's Cash from Operations peaked at $48.0 million during Q4 2021, and registered a low of -$38.4 million during Q1 2021.
  • Over the past 5 years, TherapeuticsMD's median Cash from Operations value was -$229000.0 (recorded in 2024), while the average stood at -$3.5 million.
  • As far as peak fluctuations go, TherapeuticsMD's Cash from Operations tumbled by 13402.57% in 2023, and later surged by 150704.23% in 2025.
  • TherapeuticsMD's Cash from Operations (Quarter) stood at $48.0 million in 2021, then tumbled by 37.01% to $30.2 million in 2022, then tumbled by 116.4% to -$5.0 million in 2023, then soared by 100.34% to $17000.0 in 2024, then skyrocketed by 5776.47% to $999000.0 in 2025.
  • Its last three reported values are $999000.0 in Q3 2025, $381000.0 for Q2 2025, and $699000.0 during Q1 2025.